

Fast Facts

UPMC Hillman Cancer Center is internationally recognized for its leadership in the prevention, detection, diagnosis, and treatment of cancer. As the preeminent institution in western Pennsylvania for the delivery of cancer care, the performance of basic, translational, and clinical research, and the education of the next generation of cancer researchers and physicians, UPMC Hillman Cancer Center is exceptionally well positioned to contribute to the global effort to reduce the burden of cancer.

An Impressive Network

- More than 138,000 individuals treated each year - more than 43,000 are new patients
- One of the largest integrated community cancer networks in the United States more than 70 centers in Pennsylvania, Ohio, New York, and Maryland
- More than 2,000 physicians, researchers, and staff

Driving Clinical Innovation

- State-of-the-art treatment and imaging technology such as Varian TrueBeam™ and EDGE™, Accuray CyberKnife®, positron-emission tomography/computed tomography (PET-CT), and magnetic-resonance imaging (MRI) enable UPMC's radiation oncology department to employ the latest innovative techniques such as intensity modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), and stereotactic body radiotherapy (SBRT), and MRI-guided HDR brachytherapy.
- Utilizes standardized clinical pathways through web-based decision-support tools to help guide physicians in developing a treatment plan customized for each patient's particular type and stage of cancer. Each pathway is rooted in scientific evidence and combines innovative and promising clinical trial options with the best standard-of-care therapies.
- A national leader in immunotherapy research and treatment and the first center in western Pennsylvania to offer chimeric antigen receptor (CAR) T-cell therapy, a type of immunotherapy that uses a patient's own genetically modified T cells to find and kill cancer cells.

- Pioneers in innovative surgical techniques, having performed more than 500 robotic Whipple procedures since 2008 and more than 1,900 cytoreductive surgeries for peritoneal metastases since 2001.

A Strong Commitment to Research

- Western Pennsylvania's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center Ranked 29th in NCI funding among NCI-designated centers in Fiscal Year 2019, which includes a competitive Specialized Program of Research Excellence (SPORE) cancer grant focusing on head and neck cancer, and a shared grant in ovarian cancer, in collaboration with Roswell Park Cancer Institute
- Investigators are leaders in cancer biology, cancer immunology and immunotherapy, cancer virology, biobehavioral cancer control, cancer epidemiology and prevention, cancer therapeutics, and genome stability
- 7 NCI Cancer Center Support Grant (CCSG)-supported programs and 10 CCSG-supported shared resources that provide services to investigators at UPMC Hillman Cancer Center

Accolades

- University of Pittsburgh ranked sixth in NIH funding among all universities nationwide, receiving more than \$546 million in NIH support in Fiscal Year 2019
- UPMC ranked No. 15 in the country for cancer care in 2020 by *U.S. News & World Report*
- UPMC Hillman Cancer Center comprises one of the largest networks across the U.S. to be recognized by accredited, independent organizations — including the American College of Radiation Oncology and Quality Oncology Practice Initiative — for quality, consistency, and outcomes in comprehensive cancer care.

Commercial Ventures

UPMC is actively forging long-term partnerships with technology and health care industry leaders, and acts as a hands-on equity partner, using its more than \$20 billion integrated global health enterprise to develop and evaluate products and services designed to improve health care delivery.

- UPMC Hillman Cancer Center is the original developer of Elsevier ClinicalPath (formerly known as Via Oncology), a unique web-based technology that provides physicians with evidence-based clinical algorithms that standardize best-practice cancer treatments to optimize patient outcomes. Via is now a separate company, providing this valuable service to prominent cancer centers across the country.
- UPMC Hillman Cancer Center also founded D3 Oncology Solutions, a provider of specialized radiation oncology services such as treatment planning, education, training and staffing. D3 eventually was acquired by Varian Medical Systems and is now branded under CTSI Oncology Practice Solutions.

International Centers and Partnerships

UPMC Hillman Cancer Center has international locations in Italy and Ireland. Our locations include:

- UPMC Hillman Cancer Center, San Pietro FBF Advanced Radiotherapy Center
- UPMC Salvator Mundi International Hospital
- UPMC Hillman Cancer Center, Villa Maria
- UPMC Hillman Cancer Center at UPMC Whitfield Hospital
- Bon Secours Radiotherapy Cork in partnership with UPMC Hillman Cancer Centre, Cork, Ireland

UPMC Hillman Cancer Center also collaborates with hospital systems around the world, sharing decades of expertise through clinical training, facilities management, and operational oversight to help develop and support high-quality cancer care services for their patients.

By the Numbers

Research

Clinical Trials

Active Clinical Trials at UPMC Hillman Cancer Center 443
Patient Accruals for FY 2019 5,233

Grants and Funding

Research Funding Received in FY 2019 \$122,160,924

Research Publications

Publications Over the Last Five Years. 4,555
Faculty Researchers 290

Clinical Care

Physicians and Providers

Medical Oncology/Hematology 138
Radiation Oncology. 38
Surgical Oncology 30

UPMC Hillman Cancer Center**

Staff. 1,760


Treatment Centers

Medical Oncology Centers 47
Radiation Oncology Centers. 29
International Centers and Partnerships. 5
Total Centers. 81

Net Patient Revenue \$914,812,028**

***Total includes medical oncology and radiation oncology physicians for FY 2018.*

Unique Patients Receiving Services/Treatments



UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.



UPMCHillman.com
hillmanresearch.upmc.edu